Targets › SELENOK
1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Apr 2027.
Required for Ca(2+) flux in immune cells and plays a role in T-cell proliferation and in T-cell and neutrophil migration (By similarity). Involved in endoplasmic reticulum-associated degradation (ERAD) of soluble glycosylated proteins. (UniProt, Q9Y6D0)
Open in Phaseline: the race on SELENOK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| First Affiliated Hospital of Chongqing Medical University | selenium yeast supplementation selenium cofactor for selenoprotein synthesis | SELENOP, SELENOK, SELENOW, SELENOF | Phase 2 | Depression - Major Depressive Disorder | Apr 2027 |
Depression - Major Depressive Disorder (1)
small molecule (1)
First Affiliated Hospital of Chongqing Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.